LAK therapy for hepatocellular carcinoma (six-year follow-up)

T. Takeda, I. Sakita, Hidetoshi Eguchi, M. Sakon, K. Umeshita, T. Kanai, M. Monden

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) with intrahepatic metastasis (IM) has a poor prognosis. In 1991 we carried out intra-hepatic-arterial LAK therapy for 3 HCC patients with IM. Case TY (45-year-old male) had a large tumor (diameter: 6 cm) in posterior segment with multiple intrahepatic metastases; Stage IV (T4N0M0) and underwent posterior segmentectomy (tw +: absolute non- curative operation). We carried out LAK therapy via the intra-hepatic-artery catheter. Therapeutic schedules consisted of LAK cells (1 x 109; twice/week), IL-2 (350 x 103JRU; 6 times/week) and cyclophosphamide (100 mg; once/week). We infused LAK cells 7 times in 5 weeks. Two years after LAK therapy, there were no IM stains in angiography and now, 6 and half years after this therapy, he is healthy without disease.

Original languageEnglish
Pages (from-to)858-860
Number of pages3
JournalBiotherapy
Volume12
Issue number5
Publication statusPublished - Jan 1 1998

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takeda, T., Sakita, I., Eguchi, H., Sakon, M., Umeshita, K., Kanai, T., & Monden, M. (1998). LAK therapy for hepatocellular carcinoma (six-year follow-up). Biotherapy, 12(5), 858-860.